Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways

Shengdian Wang, Lieping Chen

Research output: Contribution to journalArticle

Abstract

Cancer immunotherapy is finally entering a new era with manipulation of cosignaling pathways as a therapeutic approach, for which the principle was proved nearly two decades ago. In addition to CTLA-4, CD137 and B7-H1/PD-1 pathways are two new targets in the stage. CD137 pathway is costimulatory and its agonistic antibody delivers potent signal to drive T cell growth and activation. On the other hand, blockade of B7-H1/PD-1 pathway with antagonistic antibody has shown to protect ongoing T cell responses from impairment by immune evasion mechanism in cancer microenvironment. With these tools in hand, a mechanism-based design of combined immunotherapy with high efficacy is becoming a reality.

Original languageEnglish (US)
Pages (from-to)245-267
Number of pages23
JournalCurrent Topics in Microbiology and Immunology
Volume344
Issue number1
DOIs
StatePublished - 2010

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology (medical)
  • Immunology
  • Microbiology

Fingerprint Dive into the research topics of 'Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways'. Together they form a unique fingerprint.

  • Cite this